In 2025, the global biomarkers market has become one of the critical intersections of biotechnology, diagnostics and digital health. Biomarkers—measurable biological indicators of normal or disease processes or responses to therapies—are no longer niche research tools. Instead, they are foundational in shaping precision medicine, targeted therapies, liquid biopsies and early disease-detection strategies. For diagnostics providers, pharma/biotech companies, instrument and consumables manufacturers, and digital health startups, this surge in biomarker adoption presents a strategic inflection point: deliver deeper insights, customise treatments and reduce time to market.

Latest Developments (2024–2025)

In June 2025, the company Quanterix Corporation’s HD-X Simoa immunoassay analyzer received Class I medical-device approval in South Korea — expanding access of ultra-sensitive biomarker detection technology for diseases such as Alzheimer’s.
Researchers published an AI-driven multimodal biomarker model for early detection of cancer cachexia, integrating lab values, imaging and clinical data.
An optical biosensor using nanopillar photonic crystal architecture demonstrated detection of Alzheimer’s-related biomarkers (Aβ42/Aβ40) in undiluted serum at clinically relevant levels.
Regulatory and reimbursement changes: for example, in the U.S., states like Connecticut moved to mandate insurance coverage of biomarker tests as of January 2026 — signalling policy support for biomarker-based diagnostics.
Technological advancements: Integration of omics technologies (genomics, proteomics, metabolomics), AI for biomarker discovery/analysis and rising adoption of non-invasive tests (liquid biopsies) are reshaping the landscape.

These developments emphasise that biomarkers are moving beyond static markers into dynamic, multi-modal, data-rich frameworks — becoming strategic assets across the healthcare value chain.

Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43

Market Overview & Key Insights

Market Size & Forecast

The global biomarkers market, valued at US$58.07 billion in 2024, stood at US$62.39 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a forecasted valuation of US$104.15 billion by the end of the period.

Key Players & Emerging Innovators

Major established players include Thermo Fisher Scientific, Abbott Laboratories, Roche Diagnostics, Bio‑Rad Laboratories, Qiagen, and Agilent Technologies.

Emerging startups/institutions are pushing ultra-sensitive sensors, AI-driven biomarker models and liquid-biopsy platforms (e.g., the optical biosensor for Alzheimer’s in the academic literature mentioned above).

Key Insights

Oncology remains the largest application area, driven by demand for companion diagnostics, liquid biopsy and targeted therapies.
Diagnostics and drug-development use-cases overlap: biomarkers are critical in patient stratification, therapy monitoring, safety/efficacy endpoints, and early-disease detection.
Technologies such as immunoassays, NGS (next-generation sequencing), mass spectrometry, digital biomarkers and multiplexed panels are key enablers.
Growth in emerging geographies (Asia-Pacific) is accelerated by rising healthcare investment, chronic-disease burden and government precision-medicine initiatives.
Regional Analysis

North America

North America leads today as Drivers include high R&D investment, advanced diagnostics infrastructure, regulatory support and mature precision-medicine adoption.

Europe

Europe remains strong in biomarker research and application, with solid infrastructure for diagnostics and pharmaceuticals. The EU’s focus on precision health and cross-border collaboration (e.g., EUnetHTA) supports adoption. Growth is steady though somewhat slower than Asia-Pacific.

Asia-Pacific

Asia-Pacific is the fastest-growing region, supported by emerging healthcare markets, government initiatives, increasing diagnostics labs and rising burden of chronic diseases.

This presents opportunities for biomarker-kit manufacturers, diagnostics developers and service providers looking to localise operations.

Latin America & Middle East & Africa

These regions currently represent smaller shares, but present meaningful growth opportunities: increasing diagnostics access, rising disease burden, expanding healthcare investment. Local regulatory frameworks and reimbursement infrastructure remain nascent, which creates both challenge and opportunity.

Technology Drivers & Opportunities

Omics-driven discovery: Genomics, proteomics, metabolomics, transcriptomics and epigenetics are unlocking new biomarker candidates, enabling more sensitive and specific disease detection and stratification.
Liquid biopsies and minimally invasive diagnostics: Blood or other body-fluid biomarkers (e.g., ctDNA, exosomes) are gaining traction in early detection of cancer and other diseases.
AI, machine-learning and big-data analytics: With biomarker data being multi-dimensional (omics + clinical + imaging), AI/ML tools enhance discovery, validate signatures and integrate real-world data. For example, the AI model for cancer cachexia mentioned earlier.
Digital biomarkers and wearables: While still a sub-segment, digital biomarkers (data from sensors, wearables, apps) are growing rapidly and may overlap with traditional biomarker domains.
Personalised medicine & targeted therapies: As more therapies are designed for specific biomarker-defined populations, demand for companion diagnostics and biomarker assays rises.
Regional manufacturing/outsourcing: Opportunities exist for partnering with CDMOs or diagnostics labs in emerging markets to serve local demand for biomarker assays.
Point-of-care (POC) and multiplexed panels: The push toward rapid, multiplexed biomarker panels at the point of care opens new applications (chronic disease management, screening, monitoring).

Challenges & Barriers

Biomarker discovery and validation hurdles: Many candidates fail to validate in clinical settings. The journey from discovery to clinical adoption remains long, expensive and high-risk.
Regulatory and reimbursement complexities: Biomarker tests (especially companion diagnostics) face stringent regulatory approval and reimbursement landscapes which vary by market.
Data integration and standardisation: Variability in biomarker platforms, lack of standardised assays, heterogeneous data sets and inconsistent interpretation hamper broad adoption.
Cost considerations: High cost of advanced assays or multi-omics platforms may limit access in lower-income settings.
Clinical adoption inertia: Clinicians may be hesitant to adopt new biomarker tests without robust clinical-utility evidence, impacting market uptake.
Infrastructure limitations in emerging markets: In many geographies, limited diagnostic lab infrastructure, regulatory frameworks and reimbursement systems slow adoption.

Future Outlook (2025–2030)

The biomarkers market is poised for sustained growth through 2030, especially as diagnostics and therapeutics converge and precision-medicine models scale.
Expect wider adoption of multi-biomarker panels, integration of liquid-biopsy assays, and expansion into non-oncology areas (neurology, cardiovascular, metabolic diseases).
Digital biomarkers (wearables, sensor-derived data) will increasingly augment traditional biomarkers—creating hybrid diagnostics modalities.
Increased localisation of biomarker manufacturing and assay development in Asia-Pacific, Latin America and MEA will shift the geographic balance.
Suppliers who combine assay/kit development, data analytics, AI/ML platforms and managed-services for biomarker validation will gain competitive edge.
Renewed emphasis on point-of-care biomarker tests and decentralised diagnostics may open consumer-accessible versions of biomarker testing.
Partnerships between pharma, diagnostics, digital-health and data analytics companies will accelerate time-to-market for biomarker-driven therapies and diagnostics.

Business Opportunities

For healthcare companies, diagnostics firms, device/instrument manufacturers and digital-health startups:

Assay kit/instrument vendors: Develop high-sensitivity biomarker detection systems (immunoassays, MS-based, NGS, biosensors) for the growing demand in oncology, neurology and chronic diseases.
Companion-diagnostic developers: Partner with pharma/biotech to co-develop biomarker-driven therapies and corresponding diagnostics (drug + test model).
Digital-biomarker and analytics providers: Build platforms that integrate wearable/sensor data, clinical/omics data and apply AI to generate actionable biomarker insights for disease monitoring or preventive care.
Contract research organisations (CROs) and biomarker-validation services: Offer turnkey services for biomarker discovery, validation, regulatory submission support, and real-world data integration.
Regional service/distribution expansion: Set up labs, manufacturing or distribution in Asia-Pacific and emerging markets to capture high-growth segments.
Point-of-care biomarker solutions: Innovate POC platforms for multiplex biomarker detection (chronic diseases, screening) and collaborate with telehealth/digital-health providers for remote monitoring.
Educational & consulting services: Given complexity of biomarker validation, AI integration and regulatory pathways, advisory services around adoption strategy, data-infrastructure and reimbursement may be needed.

Key Takeaways

The biomarkers market is scaling rapidly in 2025, driven by precision medicine, targeted therapies, omics technologies and increased adoption in diagnostics and drug development.
Key applications include oncology, neurology, cardiovascular diseases and emerging areas; major technologies include immunoassays, NGS, mass spectrometry and digital biomarkers.
Regions: North America leads today; Asia-Pacific is fastest growing; Europe active; Latin America & MEA poised for expansion.
Technology drivers: omics, AI/ML, liquid biopsies, digital biomarkers, POC platforms and personalised medicine.
Challenges: validation, regulation, cost, data-standardisation, clinical adoption, infrastructural gaps.
Business opportunities abound for assay/instrument suppliers, diagnostics firms, digital-health platforms, CROs, regional service providers and point-of-care innovators.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=43

Biomarkers Market 2025: Accelerating Precision Medicine with Next-Gen Insights

Explore how the biomarkers market is evolving in 2025—fueled by omics advances, AI-driven detection and personalised medicine across diagnostics and therapeutic